Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA

The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).

Inclusion Criteria:

• Signed written informed consent
• Male or female aged >= 18 years
• Stage IIIb and IV Non Small Cell Lung Cancer histologically confirmed

Exclusion Criteria:

• Tissue and plasma samples can not be provided for mutation analysis
• Unwilling or unable to provide informed consent
• Any serious medical condition that would interfere with the subject's safety